158 related articles for article (PubMed ID: 37988952)
1. Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.
Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
ESMO Open; 2023 Dec; 8(6):102069. PubMed ID: 37988952
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
[TBL] [Abstract][Full Text] [Related]
3. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Johung KL; Yeh N; Desai NB; Williams TM; Lautenschlaeger T; Arvold ND; Ning MS; Attia A; Lovly CM; Goldberg S; Beal K; Yu JB; Kavanagh BD; Chiang VL; Camidge DR; Contessa JN
J Clin Oncol; 2016 Jan; 34(2):123-9. PubMed ID: 26438117
[TBL] [Abstract][Full Text] [Related]
4. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib.
Miao E; Eichholz JE; Lebow ES; Flynn J; Zhang Z; Walch H; Hubbeling H; Beal K; Moss NS; Yu KK; Meng A; Kelly DW; Gomez DR; Li BT; Rimner A; Schultz N; Drilon A; Imber BS; Pike LRG
Lung Cancer; 2023 Apr; 178():57-65. PubMed ID: 36780766
[TBL] [Abstract][Full Text] [Related]
6. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
[TBL] [Abstract][Full Text] [Related]
7. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China.
Li N; Xie M; Zhou Z; Sheng J; Yu X; Fan Y
Thorac Cancer; 2023 Jan; 14(3):237-245. PubMed ID: 36411716
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
10. ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases.
Tsakonas G; Kamali C; De Petris L; Friesland S; Lewensohn R; Ekman S
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32640547
[TBL] [Abstract][Full Text] [Related]
11. Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.
Dutta SW; Mack ML; Aliotta E; Ward KA; Muller DA; Larner JM; Fadul CE; Hall RD; Gentzler RD; Sheehan JP
J Neurooncol; 2020 Sep; 149(2):357-366. PubMed ID: 32902767
[TBL] [Abstract][Full Text] [Related]
12. Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.
El Shafie RA; Seidensaal K; Bozorgmehr F; Kazdal D; Eichkorn T; Elshiaty M; Weber D; Allgäuer M; König L; Lang K; Forster T; Arians N; Rieken S; Heussel CP; Herth FJ; Thomas M; Stenzinger A; Debus J; Christopoulos P
ESMO Open; 2021 Jun; 6(3):100161. PubMed ID: 34090172
[TBL] [Abstract][Full Text] [Related]
13. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
14. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
15. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
16. Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma.
Nakashima T; Nonoshita T; Hirata H; Inoue K; Nagashima A; Yoshitake T; Asai K; Shioyama Y
In Vivo; 2020; 34(1):247-253. PubMed ID: 31882485
[TBL] [Abstract][Full Text] [Related]
17. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
18. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
[TBL] [Abstract][Full Text] [Related]
19. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
